[go: up one dir, main page]

MX2007005428A - Combinaciones de agonistas del receptor nicotinico alfa 7 y de la acetilcolina. - Google Patents

Combinaciones de agonistas del receptor nicotinico alfa 7 y de la acetilcolina.

Info

Publication number
MX2007005428A
MX2007005428A MX2007005428A MX2007005428A MX2007005428A MX 2007005428 A MX2007005428 A MX 2007005428A MX 2007005428 A MX2007005428 A MX 2007005428A MX 2007005428 A MX2007005428 A MX 2007005428A MX 2007005428 A MX2007005428 A MX 2007005428A
Authority
MX
Mexico
Prior art keywords
combinations
nicotinic acetylcholine
receptor agonists
acetylcholine alpha
alpha
Prior art date
Application number
MX2007005428A
Other languages
English (en)
Inventor
Graeme Bilbe
Conrad Gentsch
Annick Vassout
Joachim Nozulak
Dominik Feuerbach
Konstanze Hurth
Hans O Kalkman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2007005428A publication Critical patent/MX2007005428A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a combinaciones que comprenden cuando menos un agonista del receptor nicotinico alfa 7 de la acetilcolina y cuando menos un compuesto que se selecciona del grupo que consiste de (a) antipsicoticos convencionales, (b) antipsicoticos atipicos, (c) mejoradores de la capacidad cognitiva, de la atencion y/o de la memoria y (d) antidepresivos, y al uso de dichas combinaciones en el tratamiento de trastornos psiquiatricos.
MX2007005428A 2004-11-05 2005-11-03 Combinaciones de agonistas del receptor nicotinico alfa 7 y de la acetilcolina. MX2007005428A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0424564A GB0424564D0 (en) 2004-11-05 2004-11-05 Organic compounds
PCT/EP2005/011787 WO2006048294A1 (en) 2004-11-05 2005-11-03 Combinations of nicotinic acetylcholine alpha 7 receptor agonists

Publications (1)

Publication Number Publication Date
MX2007005428A true MX2007005428A (es) 2007-05-18

Family

ID=33523294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005428A MX2007005428A (es) 2004-11-05 2005-11-03 Combinaciones de agonistas del receptor nicotinico alfa 7 y de la acetilcolina.

Country Status (12)

Country Link
US (2) US20080306081A1 (es)
EP (3) EP2135609A1 (es)
JP (3) JP2008518896A (es)
KR (2) KR101302898B1 (es)
CN (1) CN101039670A (es)
AU (1) AU2005300691A1 (es)
BR (1) BRPI0517647A (es)
CA (1) CA2582436C (es)
GB (1) GB0424564D0 (es)
MX (1) MX2007005428A (es)
RU (1) RU2007120690A (es)
WO (1) WO2006048294A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
US20060211686A1 (en) * 2005-03-18 2006-09-21 Abbott Laboratories Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions
EP2258359A3 (en) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
HUE042168T2 (hu) * 2008-02-29 2019-06-28 Biolab Sanus Farmaceutica Ltda Racetámot és karnitint tartalmazó gyógyszerkészítmény és eljárás elõállítására
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
BR112013001939A2 (pt) * 2010-07-26 2017-07-11 Envivo Pharmaceuticals Inc tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase
DK2675893T3 (en) 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
WO2012127393A1 (en) * 2011-03-18 2012-09-27 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
MX2023005895A (es) * 2020-11-25 2023-06-06 Vanda Pharmaceuticals Inc Tratamiento de la ansiedad al hablar en publico con un agonista del receptor nicotinico alfa 7 de la acetilcolina.
CN116761604A (zh) * 2020-11-25 2023-09-15 万达制药公司 用α-7烟碱型乙酰胆碱受体激动剂治疗当众讲话焦虑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB261309A (en) 1926-07-23 1926-11-18 Oswald Pfeiffer Improvements in collapsible grids
GB281309A (en) 1926-11-27 1928-03-29 Inventia Patent Verwert Ges Improvements in or relating to brushing machines having replaceable brush members
US3310553A (en) * 1962-09-25 1967-03-21 Pfizer & Co C Alkylated thioxathenesulfonamides
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036040A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
BR0212123A (pt) * 2001-08-24 2004-07-20 Upjohn Co 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças
US6919359B2 (en) * 2001-11-08 2005-07-19 Pfizer Inc Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
AU2003253686A1 (en) * 2002-08-01 2004-02-23 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
CA2493245A1 (en) 2002-08-14 2004-02-26 Neurosearch A/S Novel quinuclidine derivatives and their use
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AU2003284898A1 (en) * 2002-10-29 2004-05-25 Micro, Inc. Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease
EP1572300A1 (en) * 2002-12-11 2005-09-14 Pharmacia & Upjohn Company LLC Combination for the treatment of adhd
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
US8514784B2 (en) 2008-08-27 2013-08-20 Zte Corporation Method for processing downlink signal in sector portion and base station thereof
US10066977B2 (en) 2009-01-26 2018-09-04 Canon U.S. Life Sciences, Inc. Microfluidic flow monitoring

Also Published As

Publication number Publication date
EP2135609A1 (en) 2009-12-23
AU2005300691A1 (en) 2006-05-11
US20100125063A1 (en) 2010-05-20
CA2582436C (en) 2016-10-04
CA2582436A1 (en) 2006-05-11
BRPI0517647A (pt) 2008-10-14
CN101039670A (zh) 2007-09-19
GB0424564D0 (en) 2004-12-08
WO2006048294A1 (en) 2006-05-11
EP1809285A1 (en) 2007-07-25
JP2012255039A (ja) 2012-12-27
JP2014196328A (ja) 2014-10-16
KR20070073881A (ko) 2007-07-10
EP2332537A1 (en) 2011-06-15
KR20130024974A (ko) 2013-03-08
US20080306081A1 (en) 2008-12-11
KR101302898B1 (ko) 2013-09-06
RU2007120690A (ru) 2008-12-10
JP2008518896A (ja) 2008-06-05

Similar Documents

Publication Publication Date Title
MX2007005428A (es) Combinaciones de agonistas del receptor nicotinico alfa 7 y de la acetilcolina.
NO20081016L (no) Nye 1-aryl-3-azabicyklo(3.1.0)heksaner, fremstilling og bruk for å behandle nevropsykiatriske lidelser
UA95768C2 (ru) Антагонисты мускариновых рецепторов ацетилхолина
ATE435206T1 (de) Heteroarylsulfonylstilbene als 5-ht2a- antagonisten
WO2004052348A3 (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
EP1199069A3 (en) Use of an estrogen agonist/antagonist for assessing, improving, or maintaining urogenital health
IL152916A0 (en) Heteroaryl-phenyl heterobicyclic factor xa inhibitors
ATE470662T1 (de) Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor
MA28110A1 (fr) Antagonistes du recepteur d'acetylcholine muscarinique
MXPA02007289A (es) Agonistas y antagonistas novedosos de receptores de melanocortina.
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
EP1845105A4 (en) MODIFIED EXENDINES AND CORRESPONDING USES
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
CY1110170T1 (el) Ν-καρβαμοϋλμεθυλ-4(-r)-φαινυλ-2-πυρρολιδινονη, μεθοδος παρασκευης της και φαρμακευτικη χρηση αυτης
UA93531C2 (en) Novel hydrogen sulfate salt
MX2007008723A (es) Polipeptidos de yersinia spp y metodos de uso.
AU2003274307A1 (en) 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
MXPA06000664A (es) Antagonistas del receptor muscarinico de acetilcolina.
MXPA06000663A (es) Antagonistas del receptor muscarinico de acetilcolina.
IL182738A0 (en) Enantiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
NL1025710A1 (nl) Azabicyclische pyridyloxymethyl- en benzisoxazoolderivaten.
TNSN08197A1 (fr) Composition de mortier, son procede de preparation et son utilisation
BRPI0415281A (pt) antagonistas de receptor de acetilcolina muscarìnico

Legal Events

Date Code Title Description
FG Grant or registration